Cypress Capital Management (Wyoming)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cypress Capital Management (Wyoming)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13	Closed	-$10K	–	186
2021 Q4	$10K	Hold	13	–	–	0.01%	189
2021 Q3	$10K	Hold	13	–	–	0.01%	172
2021 Q2	$8K	Hold	13	–	–	0.01%	236
2021 Q1	$7K	Hold	13	–	–	0.01%	227
2020 Q4	$8K	Hold	13	–	–	0.01%	188
2020 Q3	$7K	Hold	13	–	–	0.01%	179
2020 Q2	$6K	Hold	13	–	–	0.01%	176
2020 Q1	$5K	Hold	13	–	–	0.01%	154
2019 Q4	$5K	Hold	13	–	–	﹤0.01%	157
2019 Q3	$4K	Buy	+13	New	+$4.24K	﹤0.01%	167

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cypress Capital Management (Wyoming)'s BIO Position: Q1 2022 in Review

Cypress Capital Management (Wyoming) sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 13 shares — an estimated $10K sold.

Cypress Capital Management (Wyoming) first reported a position in BIO in Q3 2019 and held it in 10 quarters. The position peaked at $10K in Q4 2021. 516 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Cypress Capital Management (Wyoming) reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Cypress Capital Management (Wyoming) sold 13 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $10K.
Cypress Capital Management (Wyoming) first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 10 quarters.
Cypress Capital Management (Wyoming)'s Bio-Rad Laboratories Class A position peaked at $10K in Q4 2021.
516 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Cypress Capital Management (Wyoming)'s 13F filing for Q1 2022, filed 9 May 2022.